| NEKTAR THERAPEUTICS |
| USA |
| Gesundheit |
| US6402683063 / A419UB |
| ITH0 (Frankfurt) / NKTR (NASDAQ) |
| FRA:ITH0, ETR:ITH0, ITH0:GR, NASDAQ:NKTR |
| - |
| https://www.nektar.com/ |
|
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in a..
>Volltext.. |
| 1994.73 Mio. EUR |
| 1514.89 Mio. EUR |
| 47.53 Mio. EUR |
| -113.15 Mio. EUR |
| -136.81 Mio. EUR |
| -5.83 EUR |
| 118.36 Mio. EUR |
| 34.05 Mio. EUR |
| -203.55 Mio. EUR |
| 9.64 |
| -24.86% |
| -32.55% |
| - |
| - |
| - |
| - |
| NEKTAR THERAPEUTICS, NEKTAR THERAPEUTIC |
| 22.09.26 |
|
||||
|